Service Level Availability – SLA
Service Level Availability or “SLA” means the targeted availability levels measured in the Production environment, as specified in the SaaS Listing which may vary according to each SaaS Offering and its component capabilities.
Global Uncertainty and Clinical Research: Why a Risk-Based Perspective Matters
Global risks in clinical trials are increasing as geopolitical instability, supply chain disruptions, and regulatory changes affect research worldwide. Learn why RBQM is essential for proactive oversight.
AI-Driven Predictive Analytics in Risk-Based Monitoring
Discover how AI-driven predictive analytics is reshaping risk-based monitoring under ICH E6(R3), enabling earlier intervention and stronger oversight.
The Cost of Poor Quality in Clinical Trials & How to Avoid It
Protocol changes and preventable risks can delay trials and drive major costs. Learn why proactive quality planning and RBQM lead to more predictable outcomes.
Milestone | We Have Just Received our ISO 9001:2015 Certificate
Cyntegrity is now ISO 9001:2015 certified. Learn how this strengthens quality governance, continuous improvement, and trust in AI-augmented RBQM solutions.
Safe Use of Large Language Models in Regulation (LLMs)
The EMA sets guiding principles for large language models (LLMs) in regulatory science. Learn practical safeguards and how the MyRBQM® Portal aligns.
Microsoft-Certified AI in Healthcare
MyRBQM® Portal is now Microsoft-Certified Healthcare AI. Learn how this strengthens trust, validation, and transparency in AI-supported clinical oversight.
Clinical Trials Global & Regional Insights Visualizer
Interactive visualizer showing global and country-level clinical trial activity and patient enrollment trends across regions from 2010 to 2022.
Big Pharma Mergers and Acquisitions: Clinical Trials Visualizer
Interactive visualizer showing how major pharmaceutical mergers and acquisitions relate to clinical trial activity, R&D spending, and market trends over time.
Phase II Vanguards Visualizer
A structured view of Phase II clinical trials led by emerging pharmaceutical and research organizations.
